銀行貸款 小額借貸 線上貸款 汽車貸款 手機貸 瘋正妹 橘子影城 古蹟交流社 東森新聞手機板 東森新聞 港書館 super娛樂城 金鈦城娛樂城 信用版娛樂城 贏家娛樂城 WG娛樂城

Orchid Pharma
ORCHPHARMA ?NSE

Orchid Pharma

?981.00-27.25 (2.70%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
977.35
Today’s high
1,010.10
52 week low
480.00
52 week high
1,094.00
Open price
1,008.25
Previous close
1,008.25
Live volume
59,243
Lower circuit
806.60
Upper circuit
1,209.90

Fundamentals

Market Cap
?5,122Cr
ROE
2.11%
P/E Ratio(TTM)
249.35
EPS(TTM)
4.05
P/B Ratio
3.98
Dividend Yield
0.00%
Industry P/E
33.86
Book Value
253.91
Debt to Equity
0.28
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
MAR '26
Revenue (Cr)
?245
+15.06%
Profit (Cr)
?22.79
+287.57%
-75093.75187.5281.3
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Revenue growthValue
1Y (TTM)+1%
3Y CAGR+19%
Profit growthValue
1Y (TTM)+19%
3Y CAGR+54%

About

Orchid Pharma Limited is a prominent company in the Cephalosporin pharmaceuticals segment, driving its sales through life-saving Active Pharmaceutical Ingredients (APIs) used to fight infections. The company's vision is to evolve into a composite and meaningfully integrated pharmaceutical corporation, competing in specialized areas to generate greater, more sustainable value. Its integrated business model empowers the company to leverage opportunities across the pharmaceutical value chain, from initial research to the global delivery of therapeutic products. The company manufactures and exports all five generations of cephalosporin products, including sterile and veterinary items, for various international markets. Through strategic alliances, Orchid Pharma enhances its market reach, which enables the delivery of superior quality products while also securing improved margins for its operations. As a testament to its innovation, Orchid is distinguished as the only Indian Pharmaceutical Company to have invented a New Chemical Entity approved in both the US and Europe.;
CEO/MD
Mr. Rajnish Rohatgi
Founded in
1992
NSE symbol
ORCHPHARMA

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Promoters
69.84%
Mutual Funds
19.43%
Retail And Others
9.05%
Foreign Institutions
0.87%
Other Domestic Institutions
0.82%

Mutual Funds Invested (4)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
?8,393.00
-136.00 (1.59%)
L
    H
    21,286.25113.5124.39
    PfizerPFIZER
    ?4,517.80
    -21.50 (0.47%)
    L
      H
      20,766.7328.744.94
      ?1,421.00
      -9.60 (0.67%)
      L
        H
        19,822.7430.615.08
        ?790.60
        +8.50 (1.09%)
        L
          H
          19,386.3932.583.81
          Livesquawk ?
          Orchid Pharma estimates global sales potential for Enmetazobactam-Cefepime at $1B-$2B.
          Livesquawk ?
          Orchid Pharma is close to a U.S. licensing deal for a novel antibiotic. Negotiations are reported to be in advanced stages, per media coverage.
          Livesquawk ?
          Orchid Pharma Q4 net profit rises 10% YoY to ?306M from ?279M. Q4 revenue remains flat YoY at ?2.37B.
          2026
          25
          May
          Quarterly & Annual Result
          Release date
          11
          Feb
          Quarterly Result
          Release date
          2025
          11
          Nov
          Quarterly Result
          Release date
          12
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks

          銀行貸款 小額借貸 線上貸款 汽車貸款 手機貸 瘋正妹 橘子影城 古蹟交流社 東森新聞手機板 東森新聞 港書館 super娛樂城 金鈦城娛樂城 信用版娛樂城 贏家娛樂城 WG娛樂城

          xxfseo.com